Member Info for SYN00GOLD

Well done all. We are at the VERY beginning of journey. Next few weeks will see some large SP rises and more impotantly will save 100K's of lives. This virus is here to stay unfortunately and its mutation which have not yet arrived. Stay safe.

Good Morning Synners,
Courtesy of Matt- here's a summary:

- A well respected poster on ADVFN had a phone call with RM at weekend
- Slight delay in start of phase 3 was due to the changes to start of the trial (as most suspected)
- First dose will be RNS'd
- Changes to Ph 3 should speed things up from trial start (as we also discussed here)
- No issues with manufacturing (in fact exploring opps to expand this). Very promising
- Trial still expected to be in 20 countries (not all straight away).
- But SNG confident of not missing the second wave
- Interferon increases the short form of ACE2 but not the longer form, which means it does not appear to boost entry points for the virus. "We were excited to discover a new form of ACE2," Dr. Jane Lucas of the University of Southampton, who co-led the study reported published yesterday in Nature Genetics, said in a statement. "We believe this may have important implications for managing COVID-19
-ACE2 short form prevents C19 gateway into cells

I believe the various parts of the Beta Interferon1a nebulized jigsaw puzzle are coming together very nicely. You will not be surprised...............HOLD, HOLD, HOLD..............we are about to unleash hell as a therapeutic treatment in the good fight against this vicious virion.

Keep safe and healthy all.

Massive news - Stand-alone its huge BUt with all other science led facts...……..

Hold for Gold.

Sorry about that Tommy. Stay strong fella :-)

TT - Could you be more precise...........lol

...........is it like a Phil Collins type smell RNS in the air :-)

I agree TT ..................things are brewing up nicely. What do you charts predict.

A contributor on my Guild thread on ADVFN had a chat with RM today. He has regularly spoken to him in the last 6 months. His post is below.

Managed to get a quick chat with RM. Limited in what he could say without making me an insider, which I have been in the past, but didn't want to be currently. Please note this is my take on the conversation, so not words directly from RM.

All going 'to plan' and he's comfortable with where they are. Phase 3 will start 'imminently' (they will RNS 1st dose) and once started will roll out quickly. He's well aware of not 'missing' the 2nd wave of patients. There is ongoing global interest, with 20 countries lined up (they won't launch in all initially). Key is less starting the trial but in making sure it recruits quickly and completes.

The changes in the trial protocol (dropping the arm and reducing numbers) has delayed things by a few weeks. He said without this change the trial would have kicked off in December, but as above, means it will complete more quickly.

I asked about the early late debate and was reassured that patients who are already in the Cytokine storm are excluded from the trial (they are easy to spot apparently), and as the phase 2 results showed, even treatment 'late' (but pre storm and within 10 days of a positive test) responded well to SNG.

No issues with manufacture or supply of nebulisers, vials etc. Labelling is being done by hand given the numbers and the different languages, which is time consuming. They are currently scoping to be able to increase drug supply significantly from current plans, so they will be ready to upscale should it get approval, and also strengthens their hand in any future negotiations.
They have about 20+ staff and many more (another 20-30) working via 3rd parties on regulatory issues and other outsourcers. Relations with the CRO and NIHR are excellent.

He again reminded me that the phase 2 results are still probably the best results seen in any trial to date.

Home trial was mentioned and he said Dec and now Jan have been very busy and suspect it should be close to being fully recruited.

He's aware of shareholders interest and the guild and how frustrating it is when we have a treatment that should save lives, but they are moving as fast as they can to get it to patients.

Another top up for me. This is going to take off this week at some point. Have a great day !

A contributor on my Guild thread on ADVFN had a chat with RM today. He has regularly spoken to him in the last 6 months. His post is below.

Managed to get a quick chat with RM. Limited in what he could say without making me an insider, which I have been in the past, but didn't want to be currently. Please note this is my take on the conversation, so not words directly from RM.

All going 'to plan' and he's comfortable with where they are. Phase 3 will start 'imminently' (they will RNS 1st dose) and once started will roll out quickly. He's well aware of not 'missing' the 2nd wave of patients. There is ongoing global interest, with 20 countries lined up (they won't launch in all initially). Key is less starting the trial but in making sure it recruits quickly and completes.

The changes in the trial protocol (dropping the arm and reducing numbers) has delayed things by a few weeks. He said without this change the trial would have kicked off in December, but as above, means it will complete more quickly.

I asked about the early late debate and was reassured that patients who are already in the Cytokine storm are excluded from the trial (they are easy to spot apparently), and as the phase 2 results showed, even treatment 'late' (but pre storm and within 10 days of a positive test) responded well to SNG.

No issues with manufacture or supply of nebulisers, vials etc. Labelling is being done by hand given the numbers and the different languages, which is time consuming. They are currently scoping to be able to increase drug supply significantly from current plans, so they will be ready to upscale should it get approval, and also strengthens their hand in any future negotiations.
They have about 20+ staff and many more (another 20-30) working via 3rd parties on regulatory issues and other outsourcers. Relations with the CRO and NIHR are excellent.

He again reminded me that the phase 2 results are still probably the best results seen in any trial to date.

Home trial was mentioned and he said Dec and now Jan have been very busy and suspect it should be close to being fully recruited.

He's aware of shareholders interest and the guild and how frustrating it is when we have a treatment that should save lives, but they are moving as fast as they can to get it to patients.

Anyone who watched Professor Horby this morning on Andrew Marr will know that most top scientists are of the belief that this virion will be around for years to come.

Scenarios such as this one imagine how the COVID-19 pandemic might play out.
Around the world, epidemiologists are constructing short- and long-term projections as a way to prepare for, and potentially mitigate, the spread and impact of SARS-CoV-2. Although their forecasts and timelines vary, modellers agree on two things: COVID-19 is here to stay, and the future depends on a lot of unknowns, including whether people develop lasting immunity to the virus, whether seasonality affects its spread, and, perhaps most importantly, new mutations:

https://www.euronews.com/2021/01/10/coronavirus-new-variant-found-in-travellers-arriving-in-japan-from-brazil

It is now forecast that deaths will exceed 100, 000 before end of Feb in UK.

If the entire worlds population were vaccinated tomorrow, the virus will continue seasonally to kill many people. The only difference to the pandemic being, the health systems throughout the world will hopefully NOT be overwhelmed (and treatments of many types and acting at differing stages) and it will become 'manageable'.

This virus with its coded genetic profile will continue to adapt to survive and thrive. Let us hope that we can manage it.
SNG -From a commercial perspective, we INDIVIDUALLY can sell or hold. We each will have thoughts on 'potential gains' to be made, from very low to very high. All the speculation here will not change the eventual outcome for the drug or its SP.

I wish each and everyone of you all the best, but arguing is pointless.

Just take a decision. I think mine is known. RM and team have my vote of confidence. Good night.

A contributor on my Guild thread on ADVFN had a chat with RM today. He has regularly spoken to him in the last 6 months. His post is below.

Managed to get a quick chat with RM. Limited in what he could say without making me an insider, which I have been in the past, but didn't want to be currently. Please note this is my take on the conversation, so not words directly from RM.

All going 'to plan' and he's comfortable with where they are. Phase 3 will start 'imminently' (they will RNS 1st dose) and once started will roll out quickly. He's well aware of not 'missing' the 2nd wave of patients. There is ongoing global interest, with 20 countries lined up (they won't launch in all initially). Key is less starting the trial but in making sure it recruits quickly and completes.

The changes in the trial protocol (dropping the arm and reducing numbers) has delayed things by a few weeks. He said without this change the trial would have kicked off in December, but as above, means it will complete more quickly.

I asked about the early late debate and was reassured that patients who are already in the Cytokine storm are excluded from the trial (they are easy to spot apparently), and as the phase 2 results showed, even treatment 'late' (but pre storm and within 10 days of a positive test) responded well to SNG.

No issues with manufacture or supply of nebulisers, vials etc. Labelling is being done by hand given the numbers and the different languages, which is time consuming. They are currently scoping to be able to increase drug supply significantly from current plans, so they will be ready to upscale should it get approval, and also strengthens their hand in any future negotiations.
They have about 20+ staff and many more (another 20-30) working via 3rd parties on regulatory issues and other outsourcers. Relations with the CRO and NIHR are excellent.

He again reminded me that the phase 2 results are still probably the best results seen in any trial to date.

Home trial was mentioned and he said Dec and now Jan have been very busy and suspect it should be close to being fully recruited.

He's aware of shareholders interest and the guild and how frustrating it is when we have a treatment that should save lives, but they are moving as fast as they can to get it to patients.

PMJH - Apologies, but could I ask that the message from Nobby is highlighted on front page till at least Monday on a few occasions. Would hate to see it lost in the stream of messages that populate this board. I'll add, normally dross from myself :-)
Cheers

Brilliant brave man :-)

it was the 'or other significant activity' that I pondered ! JV or TO

Received this today at 5.00pm. What interested me was the last line !!!
Hi XXXX,
Thank you for your email.
As you know, Synairgen are a listed company, so any material information relating to the Phase III trial or progression of SNG001 as a treatment would be reported to the market via RNS announcement.
This would include first patient dosed in the SG018 Phase III trial or other significant activity.
Best,
Alex

End of Sept SP was 1.40>>> 12 days later 2.25 :-)

Relax

I think we'll need a bigger boat to ship the volume of treatments the world will need !!

I am really looking forward to next few weeks and Synairgen's trajectory. Saul Goodman :-)

My Guess = 90% (NB-cannot count RNS re-TR-1)

Have good weekend all, keep safe, and hope all topped up for FOMO :-)

S = Sam Adams

N= Nastro Azzuro

G= Golden Sheep